Literature DB >> 21512632

Clinical Aspects of Acute Lung Insufficiency (ALI/TRALI).

Matthias Hecker1, Hans-Dieter Walmrath, Werner Seeger, Konstantin Mayer.   

Abstract

SUMMARY: Acute respiratory distress syndrome (ARDS) is a common clinical disorder caused by a variety of direct and indirect injuries to the lung, characterized by alveolar epithelial and endothelial injury resulting in damage to the pulmonary alveolar-capillary barrier. The cardinal clinical feature of ARDS, refractory arterial hypoxemia, is the result of protein-rich alveolar edema with impaired surfactant function, due to vascular leakage and vascular dysfunction with consequently impaired matching of ventilation to perfusion. Since its first description in 1967, considerable knowledge concerning the pathogenesis of ARDS has been obtained, however, a plethora of questions remain. Better understanding of the pathophysiology of ARDS has lead to the development of novel therapies, pharmacological strategies, and advances in mechanical ventilation. However, lung-protective ventilation is the only confirmed option in ARDS management improving survival, and few other therapies have translated into improved oxygenation or reduced ventilation time. But despite improvement in our understanding of the therapy and supportive care for patients with ARDS, mortality remains high. It is the purpose of this article to provide an overview of the definition, clinical features, and pathogenesis of ARDS, and to present and discuss therapeutic options currently available in order to effectively treat this severe disorder.

Entities:  

Year:  2008        PMID: 21512632      PMCID: PMC3076339          DOI: 10.1159/000117582

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  57 in total

Review 1.  Treatment of ARDS.

Authors:  R G Brower; L B Ware; Y Berthiaume; M A Matthay
Journal:  Chest       Date:  2001-10       Impact factor: 9.410

2.  Comparison of two fluid-management strategies in acute lung injury.

Authors:  Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin
Journal:  N Engl J Med       Date:  2006-05-21       Impact factor: 91.245

3.  Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids.

Authors:  G U Meduri; J M Belenchia; R J Estes; R G Wunderink; M el Torky; K V Leeper
Journal:  Chest       Date:  1991-10       Impact factor: 9.410

Review 4.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

Review 5.  Pulmonary and extrapulmonary acute respiratory distress syndrome: are they different?

Authors:  Patricia R M Rocco; Walter A Zin
Journal:  Curr Opin Crit Care       Date:  2005-02       Impact factor: 3.687

6.  High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure.

Authors:  D Dreyfuss; P Soler; G Basset; G Saumon
Journal:  Am Rev Respir Dis       Date:  1988-05

7.  Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group.

Authors:  J E Gadek; S J DeMichele; M D Karlstad; E R Pacht; M Donahoe; T E Albertson; C Van Hoozen; A K Wennberg; J L Nelson; M Noursalehi
Journal:  Crit Care Med       Date:  1999-08       Impact factor: 7.598

8.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

9.  Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.

Authors:  Roger G Spragg; James F Lewis; Hans-Dieter Walmrath; Jay Johannigman; Geoff Bellingan; Pierre-Francois Laterre; Michael C Witte; Guy A Richards; Gerd Rippin; Frank Rathgeb; Dietrich Häfner; Friedemann J H Taut; Werner Seeger
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

Review 10.  Acute lung injury and the acute respiratory distress syndrome: a clinical review.

Authors:  Arthur P Wheeler; Gordon R Bernard
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

View more
  5 in total

Review 1.  [Extracorporeal lung support].

Authors:  M Hecker; D Bandorski; A Hecker
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-22       Impact factor: 0.840

2.  Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids.

Authors:  Konstantin Mayer; Almuth Kiessling; Juliane Ott; Martina Barbara Schaefer; Matthias Hecker; Ingrid Henneke; Richard Schulz; Andreas Günther; Jingdong Wang; Lijun Wu; Joachim Roth; Werner Seeger; Jing X Kang
Journal:  Am J Respir Crit Care Med       Date:  2009-01-08       Impact factor: 21.405

Review 3.  [Nutrition and acute respiratory failure].

Authors:  M Hecker; T W Felbinger; K Mayer
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-06-07       Impact factor: 0.840

4.  Immunomodulation by fish-oil containing lipid emulsions in murine acute respiratory distress syndrome.

Authors:  Matthias Hecker; Juliane Ott; Christoph Sondermann; Martina Schaefer; Martin Obert; Andreas Hecker; Rory E Morty; Istvan Vadasz; Susanne Herold; Bernhard Rosengarten; Martin Witzenrath; Werner Seeger; Konstantin Mayer
Journal:  Crit Care       Date:  2014-04-29       Impact factor: 9.097

5.  Immunomodulation by an Omega-6 Fatty Acid Reduced Mixed Lipid Emulsion in Murine Acute Respiratory Distress Syndrome.

Authors:  Matthias Hecker; Matthias Rose; Andreas Hecker; Hartmut Dietrich; Martina B Schaefer; Natascha Sommer; Werner Seeger; Konstantin Mayer
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.